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Summary 
A number of reports have been published describing (recurrent) respiratory depression after the use of 
alfentanil intraoperatively. To evaluate the severity of respiratory depression after the administration of 
alfemanil, 49 patients undergoing general anaesthesia for abdominal hysterectomy were randomly allocated to 
one of three groups and studied in a double-blind manner. During surgery patients received no opioic:h 
(group 1), low dose (group 2) or high dose of alfentanil (group 3) . Postoperatively patients were monitored 
with pulse oximetry and respiratory inductive plethysmography. Postoperative pain was managed with PCA 
morphine. 
T hirty- nine patients completed the study. Respiratory depressar1t effects were found in all three groups. A 
hiRher number of apnoeas (at 60 minutes in group 1: 3.3 ± 1.6; group 2: 3.5 ± 1.8; group 3: 12.2 ± 2.8) and a 
higher morphine consumption was found in group 2 when compared with group l and 3. o differences 
were found among the groups in the other respiratory parameters or in terms of the number of patients with 
respiratory depression at any one time. No cases of dear-t.-ut recurrent respiratory depression were identified. 
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Introduction 
Alfentanil has become popular as an opioid suitable 
for continuous infusion perioperatively. It has a 
shorter terminal elimination half-time than fentanyl 
(tl/2 ~ of 70 min) due to its smaller steady- state 
volume of distribution, although it.s hepatic clearance 
is abo less than that of fentanyl l· l. Its short blood-
brain equilibration time results in rapid onset of 
analgesia. Alfentanil has been postulated to provide a 
better .safety index with regard to postoperative 
respiratory depression than its analogues fentanyl i!I1d 
sufentanil when used perioperatively. Nonetheless 
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there are several report~ of respiratory depression in 
the early postoperative period after the use of 
alfentanil intraoperatively4-i5. In all of these cases 
severe respiratory depression occurred some time 
after the patients were obviously fully recovered 
from anaesthesia. In most c-.ases naloxone had to be 
given, after which rapid resumption of spontaneous 
respiration occurred. T his phenomenon has been 
called recurrent, biphasic or delayed respiratory 
depression. 
This study was performed to assess the pre -
emptive analgesic effect of a high dose alfentanil 
infusion maintained throughout the intraoperative 
course. The findings of that aspect of the study are 
reported elsewherel6. It was abo recognised that this 
study could provide valuable information as to the 
respiratory depressant effects of alfentanil in the 
postoperative period. T hus part of the study was 
designed to assess the severity of depression of 
ventilation in the first three postoperative hours. 
Methods 
Ethical approval was obtained from The Toronto 
Hospital Committees for Research on Human 
Subjects. AU patients gave their written informed 
consent to participate before entering the study. 
Patient selection 
Patients scheduled for abdominal hysterectomy were 
included in the study. Inclusion t.Titeria were age 18 
to 60 years, ASA physical status 1 or 2, body weight 
between 50 to 100 kg, no significant central nervous 
system, respiratory, cardiac, hepatic or renal 
dysfunction, no previous allergies or adverse 
reac-tions with opioid ar1algesics, no history of opioid 
or substance abuse, and no history or symptoms of 
sleep apnoea syndrome. 
Randomisation and blinding procedures 
Before the start of the study, a computer generated 
randomisation schedule l7 was used to specify the 
group (1 = no opioid, 2 = low dose alfentanil, 3 = 
high dose alfentanil) to which each prospective 
patient would be assigned upon entry into the trial. 
An opaque envelope containing the group 
assignment was prepared, sealed ar1d numbered for 
each prospective patient. On the morning of surgery, 
the anaesthetist in charge of the case opened the 
patient's envelope, read its contents, and prepared the 
syringes of alfentanil for subsequent administration. 
With the exception of the ar1aesthetist, who was 
responsible for the general anaesthesia, the patients 
and personnel who collected study data were 
blinded to the treatment. 
Preoperative assessment 
On the night prior to surgery, patients were 
familiarised with the visual analogue pain scale (VAS) 
and introduced to the patient-controlled analgesia 
(PCA) pump (Abbott Life Care Infuser, Chicago, 
Illinois) and instructed in its use. Respiratory pattern 
was assessed continuously with respiratory inductive 
plethysmography (RIP - NIMS, Miami Beach, 
Florida) and haemoglobin oxygen saturation (Sp02) 
was continuously measured using pulse oximetry 
(Nellcor N -100, Nellcor Inc, Hayward, California) 
in the postoperative period (see 'Postoperative 
monitoring'). Baseline measurements of RIP and 
Sp02 were performed over a 30 minute period 
approximately 12 hours prior to surgery. Calibration 
and validation of the RIP - as well as its application 
in previous postoperative analgesic studies - have 
been described elsewherelB-20. Respiratory rate (RR), 
episodes of apnoea (AP = tidal volume of less than 
100 ml for more than 15 seconds) and episodes of 
slow respiratory rate (SRR = respiratory rate less than 
8 breaths/min persisting for more than 5 min) were 
measured continuously and recorded in five minutes 
epochs and calculated for each 30 minute interval. 
Patients were attended continuously by trained 
personnel during the entire preoperative and 
postoperative data collection periods. Respiratory 
pattern abnormalities were confirmed by the analysis 
of real-time respiratory inductive plethysmography 
output and direct observation of the patient. Episodes 
of desaturation (Sp02 <90 for 30 seconds) and the 
number of patients with respiratory depression 
(Sp02<85% for 30 seconds ar1d!or a respiratory rate 
of less than 10 for more than 15 minutes) were also 
measured and the average Sp02 was calculated for 
each 30 minutes interval. 
General anaesthesia 
Patients were kept nil per os for six hours before 
surgery. All patients received diazepam per os (5-10 
mg) two hours prior to surgery as premedication. 
Patients were assigned at random to one o f three 
groups. 
For patients in group 1, anaesthesia was induced 
with midazolam (0.05 mg kg·l) and thiopentone (3-5 
mg kg·1). In all groups muscle relaxation ar1d tracheal 
inn1bation was achieved with vecuronium (0.1-0.15 
mg kg·l). Anaesthesia was maintained with 7l!Yo N 20 
in 0 2 and isoflurane. Opioids were not adrninistered 
at induction or intraoperatively. 
For patients in group 2, anaesthesia was induced 
with alfentanil (30 pg kg·l), midazolam (0.05 mg 
kg-1), and thiopentone (3 -5 mg kg·l). Anaesthesia 
was maintained with 70% N20 in 0 2, isoflurar1e and 
bolus doses of alfentanil (10-20 J..Lg kg·l) every hour. 
For groups 1 and 2, isoflurane was titrated to 
maintain systolic blood pressure within 20% of 
baseline systolic blood pressure derived from 
preoperative ward measurements. 
For patients in group 3, anaesthesia was induced 
with midazolam (0.05 mg kg·l) and alfentanil (100 )lg 
kg·1). Anaesthesia w-ds maintained with 7l!Yo N 20 in 
0 2 and a continuous infusion of alfentanil (l-2 pg 
kg·l min·l). The alfentanil dose was adjusted to 
maintain haemodynamic variables within 20% of 
preoperative ward values by administering a bolus 
dose of alfentanil (10- 20 ~ kg-1) and increasing the 
alfentanil infusion by increments of 0.25-0.5 j.lg kg·1 
min-1. The alfentanil infusion was discontinued 30 
minutes before the anticipated end of surgery. After 
induction of anaesthesia, all patients had a radial 
arterial catheter inserted for postoperative blood 
sampling to rn!asure plasma alfentanil concentration, 
and (if necessary) to do blood ga~ analysis. Patients 
received propranolol (0.5 - 1.0 mg) if tachycardia or 
hypertension was not controlled by the above 
regimens. At the conclusion of surgery, the trachea 
was extubated after emergence and upon resumption 
of spontaneous breathing. Patients received 
supplemental 0 2 by mask and were transported to 
the postanaesthetic care unit (PACU). 
Perioperatlvt! monitoring 
All patients were continuously monitored throughout 
the procedure with a non-invasive blood pressure 
cuff, electrocardiogram, pulse oximetry, temperature 
probe, nerve stimulator and end-tidal carbon dioxide 
and anaesthetic agent analyser. For groups 1 and 2, 
mean end -tidal isoflurane concentration was 
calculated for each five minutes block after induction 
of anaesthesia until the end of surgery. 
Postoperative management 
Patients were assessed immediately upon arrival in 
the PACU. A PCA pump system was connected to 
the indwelling i.v. cannula. Every 10 minutes, 
patients were asked whether they were in need of 
pain relief. An affirmative respon~e was followed by a 
2.0 mg intravenous bolus of morphine administrated 
by the same nurse observer for all patients. The 
nurse observer was unaware of the group to which 
the patients had been assigned. This procedure was 
repeated until the patients were alert enough to 
begin using the PCA pump. The PCA pump was set 
to deliver a 1.5 mg intravenous bolus of morphine 
with a lockout time of five minutes, a maximum 
dose of 30 mg in any four hour period, and no 
continuous background infusion. This regimen was 
overseen by the Acute Pain Service (APS). APS 
personnel were unaware of the group to which the 
patients had been assigned. Morphine (mg) usage 
was calculated from hard copy records (Abbott TRN 
Printer Model TP 40). 
Postoperative pain measurement 
A 10 em visual analogue scale (with endpoints 
labelled 'no pain' and 'worst possible pain') was used 
to assess pain intensity at rest (VAS-R) two and four 
hours after completion of surgery. 
Postoperative respiratory monitoring 
When the patient arrived in the PACU, pulse 
oximetry monitoring was reinstituted and the two 
transducer bands of the respirato ry inductive 
plethysmography were attached around the rib cage 
and abdomen of the patient. Pulse oximetry and 
plethysmography were continued for three hours 
after surgery. Oxygen supplementation was 
routinely provided for the frrst 30 minutes in the 
PAC U and then discontinued . If respiratory 
depression (Sp0 2 <85% for 30 seconds or a 
respiratory rate of less than 10 for 15 minutes) 
occurred at any time an arterial blood gas sample 
was analysed. If the Sp02 persisted at <90% after 30 
seconds, supplementary oxygen was provided by 
face mask to provide an Sp02 of >90%. 
Plasma alfentanil concentration analysis 
Blood samples (10 rnl) were drawn in all patients 
from a radial artery at 30 minutes and 120 minutes 
after arrival in the PAC U. Samples were collected 
in heparinised glass vials, centrifuged immediately, 
and the separated plasma stored at - 27°C until 
analysis at the end of the study. Assays w ere 
performed by a blinded technician on samples 
obtained from patients in groups 2 and 3 only. 
Concentrations of alfentanil were measured in 
duplicate using a specific radioimmunoassay kit 
Qanssen Biotech NV Research Products) . The 
sensitivity of the assay is 0.1 ng ml·1 and the intra-
and inter-assay coefficients of variation covering the 
therapeutic range of concentrations were < 10%21. 
Adverse effects 
Nausea and vomiting were treated as needed with 
dimenhydrinate 25-50 mg. 
Statistical analysis 
Demographic, clinical, and intraoperative treatment 
variables were analysed by x2 test (frequency data) or 
one- way, between- groups ANOVA (parametric 
data) . VAS- R, morphine, plasma alfentanil concen-
trations, MRR, number of apnoeas, saturations, 
episodes of desaturation and number of patients with 
respiratory depression were analysed by two-way 
repeated measurements ANOVA using group and 
Group 1 Group 2 Group 3 
ASA stAtus* 14:0 10:2 11:2 
Age [yr] 40.4 l! .7) 46.0 (6.4) 45.2 [1.9) 
Weight [kg] 62.5 (8.1) 67.1 (12.6) 69.2 (9.2) 
Surgery duration [min] 77.8 (23.4) 83.8 (30.5) 92.3 (29.2) 
Blood loss [miJ 154 (132.2) 411 (457.4) 484 (504.4) 
Total alfentanil [mg] 0.0 3.24 (0.44) 17.98 (5.93) t 
Propranolol [mg] 0.77 (0.63)§ 0.0 0.0 
lsoflurane [%] t 1.2 (0.27)~ 0.87 (0.16) 0.0 
* Number of patients classified as ASA stAtus 1 and 2 
t Mean end-tidal isoflurane concentration in 5 min blocks 
t p=0.0001 versus Group 2 
§ p=O.OOl versus Group 2 and 3 
~ p = 0.0006 versus Group 2 
Table 1: Mean {standard devlatlon} clinJCiJi, demographic and Intraoperative treatment variables for the three 
groups 
Group 1 Group 2 Group 3 
Diagnosis 
Fibroids 9 11 10 
Endometrial carcinoma 1 1 1 
Endometriosis 2 0 2 
PMS *I Abdominal pain 2 0 0 
Procedure 
Total abdominal hysterectomy 12 10 11 
Total abdominal hysterectomy + 
Bilateral salpingo-oophorectomy 2 2 2 
Type of incision t 
Horizontal 10 7 6 
Midline 3 5 7 
* PMS = pre-menstrual syndrome 
t Type of incision was missing for one patient in Group 1 
Table 2: Frequenr;y of cllagnosls, procedure and type of JnclsJon for the tluee groups 
the independent samples factor and time after 
surgery as the repeated measures factor. Significant 
effects were followed up with Fisher's protected LSD 
test to determine the pattern of differences between 
pairs of means. Currrulative morphine conswnption 
was analysed by one-way ANOVA. 
Results 
Patient withdrawals 
Forty-nine patients were recruited into the study. 
Three were removed for protocol violations, four 
for technical problems wi th the respiratory 
inductive plethysmograph monitoring equipment 
and three for lack of arterial blood sampling (no 
arterial catheter). Thirty-nine patients completed 
the study. 
Demographic, clinical and intra- operative 
variables 
The three groups did not differ significantly on 
demographic variables (Table 1) or in frequency of 
diagnosis, incision type or surgical procedure (Table 
2). Group 3 received significantly more alfentanil 
than group 2 (p = D.OOOl). Mean isoflurane 
requirements were significantly greater in group 1 
than group 2 (p= 0.0006). Nine patients in group 1 
received propranolol (p= O.OOl) . 
Group 1 
Time after surgery VAS-R 
30 minutes Nm 
2 hours 6.2 (1.9) 
4 hours 6.8 (1.6) 
Nm = Not measured 
* p g)_006 versus Group 1 and 2 
t p = 0.0001 versus Group 2 
Group 2 Group 3 
VAS-R ALF VAS-R ALF 
Nm 35 (14.4) Nm 217 (1 07 .9)t 
5.9 (1.4) 19 (10.9) 4.0 (1.9)* 147 (93.3) t 
5.6 (2.5) Nm 3.9 (2.0)* Nm 
Table 3: Mean (standard devJaUon} VAS Jn rest (V AS-R) and mean (standard devJaUon} pfasftlij alfentanJI 
(ALF) conccntratlons after surgery 
Group Number of patients pH POz PC02 Plasma concentrations 
with respiratory depression (mrnHg) (mmHg) of alfentanll (ng m l-1) 
One episode Two episodes 30min 60 min 
0 1 7.39 (0.11) 89 (28.9) 41 (10.6) 
2 2 1 7.34 (0.03) 83 (11.0) 54 (18.9) 36 (1 .0) 10 (4.4) 
3 0 3 7.29 (0.05) 108 (71.0)* 49 (5.5) 189 (26.8) 127 (20.3) 
* Two patients in group 3 with respiratory depression received supplemental oxygen before the blood gas was drawn 
Table 4: N11mber of patlents with respiratory depressJon and the mean (st.andard devJatJon} resrdts of their blood gas and plasma 
alfentanll analysJs 
Pain and morphine consumption 
Over the four hour period, VAS-R pain scores (Table 
3) vvere significantly lovver in group 3 than in the 
other two groups (p ~.006). Cumulative rnorphi.r1e 
consumption (mg) at 180 minutes (Figure 1) was 
significantly lower in group 3 than in group 2 
(p= 0.02) . 
Plasma com:entratlon of alfentanll 
Plasma concentrations of alfentanil vvere available at 
30 minutes and 120 minutes after surgery for 10 
patients in group 2 and 10 patients in group 3 (Table 
3) . Mean alfentanil plasma concentrations in group 3 
was significantly greater than that of group 2 at 30 
and 120 minutes (p= O.OOOI). 
Postoperative respiratory monitoring 
The mean number of apnoeas (per 30 minutes) 
(Figure 2) in group 1 was significantly lower than in 
group 2 at 30 (1. 7 ± 0.9 versus 11.9 ± 3.2 for group 
1 and 2, respectively) and at 60 (3.3 ± 1.6 versus 12.2 
± 2.8 for groups 1 and 2, respectively) minutes after 
surgery (aU p ~.007). Moreover, at 60 minutes the 
mean apnoea rate in group 3 (3 . 5 ± 1.8) was 
significantly lower than in group 2 (p= 0.007) . From 
90 minu tes onward, there were no significant 
differences among the three groups. The mean 
respiratory rate (MMR) was significantly lower in 
group 3 (14. 7 ± 1.0) than in group 1 (20.9 ± 1.2) at 
30 minutes after surgery (p= 0 .0002) (Figure 3) . 
Thereafter MRR did not differ significantly among 
the groups. There was no significant difference 
among the groups in the mean number of slow 
respiratory rate episodes (SRR) or episodes of 
desaturatio n . Also no significant differences were 
found in terms of the number of patients with a 
respiratory depression at any one time (Table 4) . It 
was noted in these patients that the respiratory 
depression occurred when the patients vvere asleep 
and that they were easily aroused by verbal stimuli. 
Plasma concentrations of alfentanil did not differ 
significantly for patients with or without respiratory 
depression. There was no significant difference in 
average saturation although values for aU three groups 
decreased significantly over time from 30 to 180 
minutes after surgery (p= O.OOOI) (Figure 4). 
Adverse effects 
No adverse effects (in terms of nausea and vomiting) 
vvere seen for the duration of the study. 
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Discussion 
The present stu dy der:wnstrates that respt::-atory 
depression occurred tn at least one patient in all thrne 
Broups. One pattent in Broup 1. three patients in 
group 2 a."ld th:-ee petle:1ts \:1 group 3 experlenced 
one or two episodes of resptratory depression as 
deftned by a respiratory rate lower than 10/mtn for 
15 minutes and/or saturation lower than 85% for 30 
seconds (see Table 4) . It 'IM!S noted ~n these pet1ents 
that the resptratory depress io n occurred when the 
pattcnts ~m asleep and that they ~m eastly aroused 
by verbal slimult 
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dose alfenta:1!1 group (group 3) then ln the non 
op10id grou p (group 1) at 30 minutes. Since at that 
tl:ne point, the mean respiratory rate was 1 ~-7 for 
B~oup 3 and 20.8 for eroup 1. this was not 
cons1dered to be of clinlcel slgnlflcence. 
The number of apnoeas was found to be htgher in 
group 2 than in ~roup l at 30 minutes and in group 
1 and 3 at 60 m inutes after surgery. Furthermore the 
patients In group 2 had hlgher morphme 
consumption than the pattentx ln group 3 In the first 
90 mmutcs after surgery and a h1ghcr mean VAS 
score during U1e f~rst four hours afler ~urgery. The 
ilndlng of a higher number of apnoeu in group 2 Is 
remarkable, espectally smce no differences were 
found among the ~rou ps m the other respiratory 
parameters or in Sp~ . Group 2 was the only group 
in which the patients received isoflurane and 
alfentanil during their general anaesthesia Isoflurar1e 
is known to produce dose-dependent respiratory 
depression, although this effect is short-lived. It can 
be speculated that the finding of the higher number 
of apnoeas in group 2 is mainly caused by the higher 
morphine consumption combined with possible 
lingering effects of alfentanil. 
Other studies also have tried to assess the problem 
of respiratory depression after the use of alfentar1il. 
C02 response curve measurements are a sensitive 
way to demonstrate respiratory depression22. Two 
open studies23.24 used this method to demonstrate 
that continuous infusion of alfentanil in patients 
resulted in depression of the C02 response curve, but 
with a lesser effect on tidal volume, breathing 
frequency and PC02 levels. Goldberg et aJ!2 found 
that the C02 response slopes were depressed for 120 
minutes with a right shift of the slope in patients after 
an alfentanil-based anaesthetic. Mean plasma alfentanil 
concentrations ranged from 124.5 ng ml· l at 30 
minutes to 58.9 ng mi·l at 150 minutes. Secondary 
increases in plasma alfentanil concentrations in five 
out of 21 patients were found and eight patients 
experienced desaturation (Sp02 <90%), but no 
relationship could be demonstrated between alfentartil 
plasma concentration and the C02 response curve or 
arterial 0 2 desaturation . Also in Goldberg's study the 
episodes of desaturation most often occurred when 
the patients were asleep but arousable to verbal 
stimuli. Only one dose of alfentanil was used and no 
control group was included. 
The disadvantage of using C02 response curve 
measurements is that it requires active patient 
collaboration. Since each test must be performed 
with a large mouthpiece and nose clips, it creates 
some disturbar1ce on aw-dk.ening the subjet.t ar1d will 
counteract any respiratory depressant effects by 
arousing the patient. By using non-invasive and non 
interfering monitors such as inductive plethysmo-
graphy and oximetry we tried to create a more 
realistic clirrical PACU environment. 
In the present study the highest mean plasma 
concentration of alfentanil measured was 217 ng mi-l 
(in group 3 at 30 minutes after surgery). This value is 
in the range of the threshold for resumption of 
spontaneous breathing (100- 240 ng mi-1)25. Plasma 
concentration of alfentanil did not differ between 
patients with or without respiratory depression . 
Cases of recurrent respiratory depression are 
described4.8 which have occurred at a plasma 
concentration of 87 ng ml-1 and 95 ng rnl: 1• Sternlo 
et aJ26 recently reviewed the published case reports of 
recurrent respiratory depression and found a very 
wide rar1ge in the alfentarril doses administrated (72-
688 Jlg kg-1) and in the duration of the infusions (45 
-465 minutes). 
The cause of recurrent respiratory depression after 
the use of alfentanil remains unknown lD. The 
different theories include: 
• Secondary peaks in plasma concentrations of 
alfentanil have been demonstrated to occur2.7.12_ 
This can be caused by 'pH trapping', which 
involves the sequestration of the ionised drug in 
the acidic environment of the stomach with re-
absorption in the non- ionised form in the (less 
acid) intestine. Also the postoperative release of 
alfentanil from the muscular compartment 
(becoming more active after surgery) may 
contribute to a secondary peak in the plasma 
concentration of alfentar1iF. Both mechar1isms 
have been described in the case of fentanyl27,28_ 
However, no studies have been published that 
specifically look at these mechanisms in the case 
of alfentanil. 
• Alfentanil is known to have a large degree of 
interindividual variability in its pharmaco-
kinetics. In the present study mean plasma 
concentrations of alfentar1il were found to have 
large standard deviations (see Table 4) . Obesity. 
age, variability in the level of ex-glycoprotein, 
decreased hepatic blood flow, changes in acid-
base status and differences in the cytochrome 
P450 isozyms activity are possible factors 
responsible for the large interindividual 
differences in the pharmocokinetic profile of 
alfentani!'/.29,30. Furthermore it is known that 
drugs like propofoPI.32, dexmedetomine33, 
erythromycin34, cimetidine3S and fluconazole36 
can influence the clearance of alfentanil by 
interference in its metabolism. 
• Patients that are alert and awake on arrival in the 
recovery room are usually 'left alone' because 
they seem to be doing welL This means that after 
extubation, trar1sport to the PACU ar1d the irritial 
assessments on arrival in the PACU these patients 
may not receive any further stimulation. The 
decreased stimulation in these patients, combined 
with a lingering opioid effect, can be a factor in 
some cases of recurrent respiratory depression9,37. 
nus theory is supported by the fact that most 
cases of recurrent respiration depression occurred 
15 minutes or more after extubation25. Also the 
finding of very lmv pH values at the time of 
recurrent respiratory depression suggests that the 
respiratory depression evolved over some times. 
In the present study and in the study of Goldberg 
et al12 , patients who had an episode of 
desaturation appeared to be asleep but could be 
easily aroused when stimulated. 
In this controlled, randomised, double-blind study 
respiratory depressant effects were found in post 
abdominal hysterectomy patients who received no 
opioids, low or high doses of alfentanil during 
general anaesthesia. No cases of clear-cut recurrent 
respiratory depression were identified. 
Supported by a grant from Janssen Research Foundation 
and grant #MT-12052 from the Medical Research 
Council of Canada (JK). Presented Jn part at the Annual 
Meeting of the Canadlan Anaesthetlsts Soclety. Ottawa, 
Ontario, 1995. 
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